Literature DB >> 24444694

Evolution of a mesoporous bioactive glass scaffold implanted in rat femur evaluated by (45)Ca labeling, tracing, and histological analysis.

Baiyan Sui1, Gaoren Zhong, Jiao Sun.   

Abstract

Mesoporous bioactive glass (MBG) as a biodegradable scaffold with a nanostructure has attracted significant attention. However, the in vivo evolution of MBG, which includes in situ degradation, the local effect induced by degradation, and the disposition of degradation products, remains unclear. In this study, we performed in situ labeling and synthesis of an MBG scaffold for the first time using (45)CaCl2. The obtained (45)Ca-MBG scaffolds possessed a mesoporous-macroporous cross-linked structure. These (45)Ca-MBG scaffolds were implanted in critical-sized rat femur defects (3 × 3 mm) for 1 day and for 1, 4, 8, and 12 weeks and analyzed by isotopic quantitative tracing. The results illustrated that the MBG scaffolds gradually degraded over time and persisted at a local level of approximately 9.63% at week 12. This finding suggests that only a very small amount of MBG-released calcium ions may have been transformed into calcium components of the new bone matrix. The research also confirmed that the active ingredients derived from the degradation of MBG scaffolds could actively regulate the mRNA expression levels of osteoblast-related genes in rat bone marrow-derived mesenchymal stem cells (rBMSCs) and promote bone regeneration in vivo. Moreover, through isotopic tracing of the entire body, (45)Ca, which disappeared in situ after implantation, could be detected in the heart, lungs, spleen, kidneys, intestines, and brain via the blood and was mainly accumulated in distal bone tissue, including the radius and cranium. However, (45)Ca radioactivity in the body tissues significantly decreased or disappeared after 12 weeks. Systemic toxicological studies on MBG scaffolds demonstrated the degradation products that spread to major organs did not cause abnormal histopathological changes. The above discoveries comprehensively address crucial issues regarding the application of MBG in vivo, and these findings provide a scientific basis for introducing a material with mesoporous structure into clinical applications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24444694     DOI: 10.1021/am4056886

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  4 in total

1.  HnRNPL inhibits the osteogenic differentiation of PDLCs stimulated by SrCl2 through repressing Setd2.

Authors:  Xiaoshi Jia; Richard J Miron; Chengcheng Yin; Hudi Xu; Tao Luo; Jiwei Wang; Rong Jia; Min Wu; Yufeng Zhang; Yuhong Li
Journal:  J Cell Mol Med       Date:  2019-02-12       Impact factor: 5.310

Review 2.  Foam Replica Method in the Manufacturing of Bioactive Glass Scaffolds: Out-of-Date Technology or Still Underexploited Potential?

Authors:  Elisa Fiume; Sara Ciavattini; Enrica Verné; Francesco Baino
Journal:  Materials (Basel)       Date:  2021-05-24       Impact factor: 3.623

3.  Mesoporous Bioactive Glass Functionalized 3D Ti-6Al-4V Scaffolds with Improved Surface Bioactivity.

Authors:  Xiaotong Ye; Sander Leeflang; Chengtie Wu; Jiang Chang; Jie Zhou; Zhiguang Huan
Journal:  Materials (Basel)       Date:  2017-10-27       Impact factor: 3.623

4.  Drug-loadable Mesoporous Bioactive Glass Nanospheres: Biodistribution, Clearance, BRL Cellular Location and Systemic Risk Assessment via (45)Ca Labelling and Histological Analysis.

Authors:  Baiyan Sui; Gaoren Zhong; Jiao Sun
Journal:  Sci Rep       Date:  2016-09-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.